Retrophin (RTRX) Cut to Sell at BidaskClub

Share on StockTwits

BidaskClub lowered shares of Retrophin (NASDAQ:RTRX) from a hold rating to a sell rating in a research note published on Wednesday.

Several other research firms have also issued reports on RTRX. Nomura initiated coverage on Retrophin in a research note on Monday, November 19th. They issued a buy rating and a $57.00 price objective on the stock. ValuEngine lowered Retrophin from a strong-buy rating to a buy rating in a research note on Thursday, January 17th. Zacks Investment Research lowered Retrophin from a hold rating to a strong sell rating in a research note on Thursday, November 8th. Finally, Jefferies Financial Group initiated coverage on Retrophin in a research note on Tuesday, October 30th. They issued a buy rating and a $44.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $48.00.

Shares of NASDAQ RTRX opened at $20.95 on Wednesday. Retrophin has a 52 week low of $19.77 and a 52 week high of $33.00. The company has a quick ratio of 4.99, a current ratio of 5.04 and a debt-to-equity ratio of 0.60. The company has a market cap of $870.74 million, a P/E ratio of -13.97 and a beta of 1.38.

In other news, COO Neil F. Mcfarlane sold 11,125 shares of the stock in a transaction that occurred on Thursday, December 20th. The stock was sold at an average price of $22.32, for a total transaction of $248,310.00. Following the transaction, the chief operating officer now owns 35,360 shares in the company, valued at $789,235.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Steve Aselage sold 2,130 shares of the stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $21.44, for a total value of $45,667.20. Following the transaction, the chief executive officer now owns 258,707 shares in the company, valued at approximately $5,546,678.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,428 shares of company stock worth $997,118. 3.67% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Macquarie Group Ltd. increased its stake in Retrophin by 17.6% during the 4th quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock worth $51,278,000 after acquiring an additional 339,588 shares during the period. Legal & General Group Plc increased its stake in Retrophin by 17.2% during the 4th quarter. Legal & General Group Plc now owns 15,866 shares of the biopharmaceutical company’s stock worth $360,000 after acquiring an additional 2,325 shares during the period. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Retrophin by 318.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,785 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 10,491 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in shares of Retrophin by 78.5% in the 4th quarter. Squarepoint Ops LLC now owns 79,893 shares of the biopharmaceutical company’s stock valued at $1,808,000 after purchasing an additional 35,137 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its holdings in shares of Retrophin by 4.0% in the 4th quarter. Perceptive Advisors LLC now owns 3,342,038 shares of the biopharmaceutical company’s stock valued at $49,782,000 after purchasing an additional 129,167 shares in the last quarter.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Story: Trading Stocks – What are percentage gainers?

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Union Bankshares  Rating Lowered to Sell at ValuEngine
Union Bankshares Rating Lowered to Sell at ValuEngine
Five Prime Therapeutics  Stock Rating Upgraded by ValuEngine
Five Prime Therapeutics Stock Rating Upgraded by ValuEngine
Old Second Bancorp  Lowered to “Sell” at ValuEngine
Old Second Bancorp Lowered to “Sell” at ValuEngine
Vanguard Consumer Staples ETF  to Issue Quarterly Dividend of $0.75 on  March 26th
Vanguard Consumer Staples ETF to Issue Quarterly Dividend of $0.75 on March 26th
MARK.SPACE  Trading 16.6% Higher  Over Last 7 Days
MARK.SPACE Trading 16.6% Higher Over Last 7 Days
Bittwatt Price Down 28.9% Over Last 7 Days
Bittwatt Price Down 28.9% Over Last 7 Days


Leave a Reply

 
© 2006-2019 Zolmax.